Purple Biotech (ADR) (PPBT)
Develops CAPTN-3 tri-specific cancer antibodies and other oncology drug candidates.
Something off on this page? Send us feedback.
Develops oncology drug candidates around CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, while CM24 and NT219 await partnering or added investment. With no current revenue, its model depends on advancing therapies to commercialization or out-licensing.
Develops oncology candidates centered on CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies designed to engage tumor targets, T cells, and NK cells. IM1240 targets 5T4-positive tumors, while IM1305 addresses TROP2-expressing solid tumors. CM24, an anti-CEACAM1 antibody, and NT219, an IRS1/2 and STAT3 inhibitor, are clinical-stage non-core programs that require a partner or additional investment to advance.
Operates from Israel with a lean team and relies extensively on contract research organizations, manufacturers, academic investigators, and collaborators across preclinical, clinical, and manufacturing work. No current candidate generates revenue; development and potential commercialization or out-licensing depend on further testing, regulatory approval, financing, and external execution.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.1M · Total debt $134.0K · Total assets $14.2M · Shareholders' equity $12.3M
- Revenue
- $0
- Operating income
- −$1.3M
- Net income
- $441.0K
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 54.79% | 75.7K ADS | |
| Otherremainder | 45.21% | 62.4K ADS |
138.1K ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Susquehanna International Group, LLPInstitution | 38.67% | 53,403 ADS | 13Fas of Mar 31, 2026 |
Smartharvest Portfolios, LLCInstitution | 13.13% | 18,127 ADS | 13Fas of Mar 31, 2026 |
BNP Paribas Arbitrage, SNCInstitution | 1.42% | 1,957 ADS | 13Fas of Mar 31, 2026 |
Rhumbline AdvisersInstitution | 0.51% | 710 ADS | 13Fas of Mar 31, 2026 |
Simplex Trading, LLCInstitution | 0.43% | 597 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Aptevo Therapeutics
Direct 5T4 overlap through tumor-local T- and NK-cell activation.
- AstraZeneca (ADR)
Datroway and danvatirsen span TROP2 and STAT3 oncology competition.
- Gilead Sciences
Trodelvy is an established TROP2 ADC benchmark for solid tumors.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Purple Biotech (ADR) | $1.84 | −6.84% | $273.4K | — | — | — | — |
| Aptevo Therapeutics | $2.32 | −11.47% | $5.7M | — | — | — | — |
| AstraZeneca (ADR) | $163.56 | +1.18% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Median | 24.3 | 15.8 | 5.1 | +8.3% |